NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIMH E-070-2023-0-PC-01 SYSTEMS AND METHODS FOR MULTICHANNEL INDIVIDUALIZED STIMULATION THERAPY PCT PCT PCT/US2024/023876 Expired
NIDDK E-059-2024-0-US-01 The Redesign of the Terminal Inverted Repeats and Transposase Protein of the piggyBat Transposon from Myotis Lucifugus Results in Hyperactivity in Human Cells US 63/632,275 Expired
NCI E-053-2019-0-CN-11 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES CN DIV 202410413639.6 Pending
NHGRI E-141-2024-0-US-01 CIRCULATING HEPATIC BIOMARKERS ASSOCIATED WITH METHYLMALONIC ACIDEMIA AND METHODS OF THEIR USE US 63/631,025 Expired
NCATS E-046-2021-0-HK-02 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF HK EP 62024089644.4 Pending
NHGRI E-134-2023-0-PC-01 SYNTHETIC MMAB GENES AND AAV VECTORS TO TREAT COBALAMIN B DEFICIENCY PCT PCT PCT/US2024/023432 Expired
NIAID E-160-2021-0-US-02 AUGMENTATION OF INNATE AND ADAPTIVE IMMUNITY BY INHIBITION OF INTERACTION OF LILRBS WITH MHC-1 US National Stage 18/699,057 Pending
NCI E-045-2024-0-US-01 POTENT FGFR4-TARGETED ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR TREATING CANCERS EXPRESSING FGFR4 US 63/575,037 Expired
NIA E-207-2021-0-US-02 COMPOUNDS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE US CIP 18/627,191 Pending
NIA E-090-2024-0-US-01 S-HYDROXYCHLOROQUINE, OPTIONALLY WITH TAUROURSODEOXYCHOLIC ACID AND/OR 3,3′-DIINDOLYLMETHANE, FOR TREATING AND/OR PREVENTING NEUROLOGICAL DISORDERS US 63/574,481 Expired
NINDS E-061-2023-0-PC-01 SYSTEMS AND METHODS FOR PATTERNED MULTI-SLICE EXCITATION IN MAGNETIC RESONANCE IMAGING PCT PCT PCT/US2024/022852 Expired
NCATS E-001-2023-2-US-01 MULTI-CYCLIC IRAK1 AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF US 63/573,618 Abandoned
NIAID E-197-2023-2-US-01 ANTI-SARS-CoV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF [COM5, STAR] US 63/574,175 Expired
NCI E-280-2016-0-US-02 METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME US CON 18/623,529 Pending
NCI E-101-2024-0-US-01 METHODS TO IDENTIFY AND SELECTIVELY EXPAND TUMOR ANTIGEN-SPECIFIC
T CELLS . 		US 63/572,693 Expired
NCI E-027-2024-0-US-01 METHODS OF DETECTING LOSS OF HETEROZYGOSITY AND DAMAGING MUTATIONS IN IMMUNERELATED GENES IN LIQUID BIOPSIES US 63/572,760 Expired
NCI E-136-2023-0-PC-01 ALLOSTERIC INHIBITORS OF THE PLK1 POLO BOX DOMAIN, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER PCT PCT PCT/US2024/022328 Expired
NCI E-103-2023-0-PC-01 METHODS FOR ENHANCING THE IMMUNOGENICITY OF CELLULAR VACCINES PCT PCT PCT/US2024/022230 Expired
NICHD E-151-2021-0-US-02 NUCLEAR MAGNETIC RESONANCE METHODS OF DETERMINING HOMEOSTATIC
PERTURBATIONS 		US National Stage 18/697,168 Pending
NIAID E-154-2017-0-US-05 NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE US CON 18/619,995 Pending
NCATS E-072-2022-1-CN-01 MULTI-CYCLC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CN National Stage 202280065799.5 Pending
NCI E-133-2016-0-EP-12 FLT3-Specific Chimeric Antigen Receptors and Methods Using Same EP DIV 24167685.7 Pending
NCI E-169-2021-0-KR-01 MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE KR National Stage 10-2024-7010519 Pending
NCI E-087-2024-0-US-01 RADIOLABELED GLYPICAN-3 (GPC3)-SPECIFIC SINGLE DOMAIN ANTIBODY AND USE THEREOF AS AN IMAGING AGENT FOR DETECTION OF GPC3-POSITIVE TUMORS US 63/570,344 Expired
NHLBI E-080-2023-0-PC-01 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F]
FLUOROCELLOTRIOSE 		PCT PCT PCT/US2024/021440 Expired
NHLBI E-188-2021-0-CN-01 ANTI-CMPL DIVALENT SCFV AND USES THEREOF CN National Stage 202280065162.6 Pending
NIAID E-228-2016-1-KR-17 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof KR DIV 10-2024-7010062 Pending
NCATS E-046-2021-0-HK-01 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF HK CN 62024089225.2 Pending
NCI E-054-2023-0-PC-01 T CELL RECEPTORS TARGETING Y220C OR R175H MUTATION IN P53 PCT PCT PCT/US2024/021425 Expired
NIAID E-270-2015-0-US-06 SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES US CON 18/615,011 Pending
NIAID E-060-2015-0-US-18 NOVEL MULTIVALENT NANOPARTICLE-BASED VACCINES US DIV 18/615,895 Pending
NCATS E-082-2021-0-EP-01 COMPOSITIONS FOR THE TREATMENT OF FOOD AND CHEMICAL ADDICTION AND METHODS OF MAKING AND USING SAME EP National Stage 22873333.3 Pending
NCATS E-004-2016-0-AU-02 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF AU DIV 2024201890 Pending
NCATS E-082-2021-0-US-02 COMPOSITIONS FOR THE TREATMENT OF FOOD AND CHEMICAL ADDICTION AND METHODS OF MAKING AND USING SAME US National Stage 18/694,167 Pending
NCATS E-172-2021-0-EP-01 SYNTHETIC HUMANIZED LLAMA NANOBODY LIBRARY AND USE THEREOF TO IDENTIFY SARS-COV-2 NEUTRALIZING ANTIBODIES EP National Stage 22782640.1 Abandoned
CC E-242-2023-0-US-01 SYSTEMS AND METHODS FOR AN AUGMENTED REALITY GUIDANCE SYSTEM US 63/568,346 Expired
NHLBI E-146-2023-0-US-01 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF US ORD 18/610,978 Pending
NCI E-169-2021-0-EP-01 MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE EP National Stage 22777538.4 Pending
NHLBI E-188-2021-0-IL-01 ANTI-CMPL DIVALENT SCFV AND USES THEREOF IL National Stage 311590 Pending
NEI E-131-2022-0-PCT-01 METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION PCT PCT PCT/US2024/020294 Expired
NCATS E-041-2021-3-PC-01 Combinations of Retinaldehyde Dehydrogenase 1 (RALDH1) Inhibitors and Immunostimulators and Methods Using Same PCT PCT PCT/US2024/020160 Expired
NIDCR E-094-2023-0-PCT-02 METHODS FOR PRODUCING STABLE HUMAN CHONDROCYTES AND THEIR USE PCT PCT PCT/US2024/020102 Expired
NCATS E-172-2021-0-US-02 SYNTHETIC HUMANIZED LLAMA NANOBODY LIBRARY AND USE THEREOF TO IDENTIFY
SARS-COV-2 NEUTRALIZING ANTIBODIES 		US National Stage 18/692,570 Abandoned
NIAID E-052-2017-4-HK-02 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection HK CN 42024088832.1 Abandoned
NIAID E-117-2024-0-US-01 RESPIRATORY SYNCYTIAL VIRUS (RSV) G AND F ANTIBODIES WITH HIGH RSV-NEUTRALIZING POTENCY US 63/566,064 Expired
NCI E-076-2024-0-US-01 T CELL RECEPTORS TARGETING E545K OR N345K MUTATION IN PIK3CA US 63/565,764 Expired
NCATS E-179-2018-0-US-03 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA US CON 18/605,319 Pending
NCI E-190-2014-0-US-02 VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS US CON 18/605,198 Pending
NCATS E-172-2021-0-JP-01 SYNTHETIC HUMANIZED LLAMA NANOBODY LIBRARY AND USE THEREOF TO IDENTIFY SARS-COV-2 NEUTRALIZING ANTIBODIES JP National Stage 2024-516630 Abandoned
NCI E-147-2024-0-US-01 Beta-Catenin Inhibitors and Degraders
(LBR License revocation underway Jan 2025) 		US 63/564,573 Abandoned